Vivanza Biosciences Limited (BOM:530057)
India
· Delayed Price · Currency is INR 2.020
+0.090 (4.66%)
At close: Mar 10, 2026
Vivanza Biosciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 1,100 | 74.23 | 278.35 | 178.07 | 104 | 98.88 | Upgrade
|
| Other Revenue | 1.36 | 0.48 | 0.54 | 3.47 | 7.99 | 0.51 | Upgrade
|
| Revenue | 1,102 | 74.72 | 278.89 | 181.54 | 111.99 | 99.4 | Upgrade
|
| Revenue Growth (YoY) | 870.71% | -73.21% | 53.62% | 62.10% | 12.67% | 3.31% | Upgrade
|
| Cost of Revenue | 1,091 | 68.21 | 259.51 | 165.06 | 96.54 | 91.53 | Upgrade
|
| Gross Profit | 10.86 | 6.51 | 19.39 | 16.48 | 15.46 | 7.87 | Upgrade
|
| Selling, General & Admin | 6 | 5.98 | 4.51 | 3.51 | 3.24 | 3.47 | Upgrade
|
| Other Operating Expenses | 3.15 | 3.44 | 3.67 | 1.6 | 3.65 | 1.51 | Upgrade
|
| Operating Expenses | 9.29 | 9.56 | 8.3 | 5.13 | 6.96 | 5.08 | Upgrade
|
| Operating Income | 1.58 | -3.05 | 11.08 | 11.35 | 8.5 | 2.78 | Upgrade
|
| Interest Expense | -2.93 | -3.51 | -4.13 | -4.19 | -4.06 | -4.68 | Upgrade
|
| Interest & Investment Income | - | - | - | - | - | 4.23 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.09 | -0.09 | - | - | -1.1 | -1.1 | Upgrade
|
| Other Non Operating Income (Expenses) | -0 | -0 | - | - | -0 | - | Upgrade
|
| EBT Excluding Unusual Items | -1.45 | -6.66 | 6.95 | 7.16 | 3.33 | 1.23 | Upgrade
|
| Pretax Income | -1.45 | -6.66 | 6.95 | 7.16 | 3.33 | 1.23 | Upgrade
|
| Income Tax Expense | 0.08 | 0.08 | 1.48 | 1.18 | 0 | 0.48 | Upgrade
|
| Net Income | -1.53 | -6.74 | 5.47 | 5.98 | 3.33 | 0.75 | Upgrade
|
| Net Income to Common | -1.53 | -6.74 | 5.47 | 5.98 | 3.33 | 0.75 | Upgrade
|
| Net Income Growth | - | - | -8.52% | 79.67% | 342.02% | - | Upgrade
|
| Shares Outstanding (Basic) | 40 | 40 | 39 | 40 | 40 | 40 | Upgrade
|
| Shares Outstanding (Diluted) | 40 | 40 | 39 | 40 | 40 | 40 | Upgrade
|
| Shares Change (YoY) | -1.23% | 2.32% | -2.27% | - | - | - | Upgrade
|
| EPS (Basic) | -0.04 | -0.17 | 0.14 | 0.15 | 0.08 | 0.02 | Upgrade
|
| EPS (Diluted) | -0.04 | -0.17 | 0.14 | 0.15 | 0.08 | 0.02 | Upgrade
|
| EPS Growth | - | - | -6.40% | 80.21% | 340.72% | - | Upgrade
|
| Free Cash Flow | - | -25.07 | 20.06 | -9.46 | 24.67 | -27.86 | Upgrade
|
| Free Cash Flow Per Share | - | -0.63 | 0.51 | -0.24 | 0.62 | -0.70 | Upgrade
|
| Gross Margin | 0.99% | 8.71% | 6.95% | 9.08% | 13.80% | 7.91% | Upgrade
|
| Operating Margin | 0.14% | -4.08% | 3.97% | 6.25% | 7.58% | 2.80% | Upgrade
|
| Profit Margin | -0.14% | -9.02% | 1.96% | 3.30% | 2.97% | 0.76% | Upgrade
|
| Free Cash Flow Margin | - | -33.55% | 7.19% | -5.21% | 22.03% | -28.02% | Upgrade
|
| EBITDA | 1.73 | -2.91 | 11.2 | 11.38 | 8.57 | 2.88 | Upgrade
|
| EBITDA Margin | 0.16% | -3.90% | 4.02% | 6.27% | 7.65% | 2.90% | Upgrade
|
| D&A For EBITDA | 0.15 | 0.14 | 0.12 | 0.03 | 0.07 | 0.1 | Upgrade
|
| EBIT | 1.58 | -3.05 | 11.08 | 11.35 | 8.5 | 2.78 | Upgrade
|
| EBIT Margin | 0.14% | -4.08% | 3.97% | 6.25% | 7.58% | 2.80% | Upgrade
|
| Effective Tax Rate | - | - | 21.27% | 16.48% | 0.12% | 38.99% | Upgrade
|
| Revenue as Reported | 1,102 | 74.85 | 278.89 | 182.82 | 112.29 | 103.94 | Upgrade
|
| Advertising Expenses | - | 0.05 | 0.04 | 0.08 | 0.03 | 0.03 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.